AN2 Therapeutics (ANTX) CDO receives new stock options and RSU grants

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

AN2 Therapeutics Chief Development Officer Sanjay Chanda reported new equity awards. On February 20, 2026, he received a grant of stock options for 77,000 shares at an exercise price of $0.00 per share, vesting monthly over four years from January 1, 2026.

He also acquired 38,000 shares of common stock as restricted stock units that vest annually in four installments from January 1, 2026, subject to continued service. Following these awards, he directly holds 77,000 options and 118,823 common shares, which include previously granted RSUs and shares purchased under the 2022 Employee Stock Purchase Plan.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Chanda Sanjay

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	77,000	$0.00	--
Grant/Award	Common Stock	38,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 77,000 shares (Direct); Common Stock — 118,823 shares (Direct)

Footnotes (1)

Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025. The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Form 4 Insider Transactions: What Each Field Means →

02/23/2026 - 04:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chanda Sanjay

(Last)

(First)

(Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/20/2026		A		38,000⁽¹⁾	A	$0	118,823⁽²⁾⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$1.04	02/20/2026		A		77,000		⁽⁴⁾	02/19/2036	Common Stock	77,000	$0	77,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

2. Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date.

3. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025.

4. The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Remarks:

Exhibits:

	/s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did AN2 Therapeutics (ANTX) report for Sanjay Chanda?

AN2 Therapeutics reported that Chief Development Officer Sanjay Chanda received equity awards on February 20, 2026. He was granted 77,000 stock options and 38,000 restricted stock units, both subject to multi-year vesting schedules tied to his continued service with the company.

How many stock options did AN2 Therapeutics (ANTX) grant to Sanjay Chanda?

Sanjay Chanda received stock options covering 77,000 AN2 Therapeutics shares. These options vest in equal monthly installments over four years starting January 1, 2026, and were granted at an exercise price of $0.00 per share, subject to his continued service through each vesting date.

What restricted stock unit (RSU) awards did Sanjay Chanda receive from AN2 Therapeutics (ANTX)?

He received 38,000 AN2 Therapeutics common shares in the form of restricted stock units. One-quarter of these RSUs vest annually over four years from January 1, 2026, contingent on his continuous service, adding to earlier RSU grants awarded in 2024 and 2025.

What is Sanjay Chanda’s total AN2 Therapeutics (ANTX) common stock holding after these awards?

After the February 20, 2026 grants, Sanjay Chanda directly holds 118,823 AN2 Therapeutics common shares. This figure reflects new RSUs, prior RSU awards from 2024 and 2025, and an additional 5,000 shares purchased under the company’s 2022 Employee Stock Purchase Plan.

How do Sanjay Chanda’s AN2 Therapeutics (ANTX) stock options vest over time?

The 77,000 stock options vest in 48 equal monthly installments. Vesting begins on January 1, 2026, with 1/48th of the options vesting each month, provided Sanjay Chanda remains in continuous service with AN2 Therapeutics through each applicable vesting date.

What are the vesting terms for Sanjay Chanda’s prior AN2 Therapeutics (ANTX) RSU awards?

Prior RSU awards include 27,500 units vesting annually over four years from January 1, 2024 and 50,250 units vesting annually over four years from January 1, 2025. Each tranche requires Sanjay Chanda’s continuous service through the related vesting dates.